Safety of megadose meropenem in the empirical treatment of nosocomial sepsis: a pilot randomized clinical trial

Link to article at PubMed

Future Microbiol. 2023 May 4. doi: 10.2217/fmb-2022-0170. Online ahead of print.


Objective: To evaluate the safety of megadose meropenem as empirical treatment of nosocomial sepsis. Materials & methods: Critically ill patients diagnosed with sepsis received either high-dose (2 g every 8 h) or megadose (4 g every 8 h) meropenem as an intravenous infusion over 3 h. Results: A total of 23 patients with nosocomial sepsis were eligible and included in the megadose (n = 11) or high-dose (n = 12) group. No treatment-related adverse events were observed during a 14-day follow-up. Clinical response was also comparable between the groups. Conclusion: Megadose meropenem may be considered for empirical treatment of nosocomial sepsis without serious concern regarding its safety.

PMID:37140270 | DOI:10.2217/fmb-2022-0170

Leave a Reply

Your email address will not be published. Required fields are marked *